These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 36161511

  • 1. Flare on [18F]PSMA-1007 PET/CT after short-term androgen deprivation therapy and its correlation to FDG uptake: possible marker of tumor aggressiveness in treatment-naïve metastatic prostate cancer patients.
    Malaspina S, Ettala O, Tolvanen T, Rajander J, Eskola O, Boström PJ, Kemppainen J.
    Eur J Nucl Med Mol Imaging; 2023 Jan; 50(2):613-621. PubMed ID: 36161511
    [Abstract] [Full Text] [Related]

  • 2. Prospective study on the effect of short-term androgen deprivation therapy on PSMA uptake evaluated with 68Ga-PSMA-11 PET/MRI in men with treatment-naïve prostate cancer.
    Ettala O, Malaspina S, Tuokkola T, Luoto P, Löyttyniemi E, Boström PJ, Kemppainen J.
    Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):665-673. PubMed ID: 31879814
    [Abstract] [Full Text] [Related]

  • 3. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 Mar; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 4. Stereotactic Radiotherapy for Lesions Detected via 68Ga-Prostate-specific Membrane Antigen and 18F-Fluorodexyglucose Positron Emission Tomography/Computed Tomography in Patients with Nonmetastatic Prostate Cancer with Early Prostate-specific Antigen Progression on Androgen Deprivation Therapy: A Prospective Single-center Study.
    Pan J, Wei Y, Zhang T, Liu C, Hu X, Zhao J, Gan H, Liu W, Zhu B, Wu J, Wang B, Song S, Ye D, Zhu Y.
    Eur Urol Oncol; 2022 Aug; 5(4):420-427. PubMed ID: 35304107
    [Abstract] [Full Text] [Related]

  • 5. The effect of androgen deprivation therapy on 68Ga-PSMA tracer uptake in non-metastatic prostate cancer patients.
    Onal C, Guler OC, Torun N, Reyhan M, Yapar AF.
    Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):632-641. PubMed ID: 31732768
    [Abstract] [Full Text] [Related]

  • 6. Phase 2 trial of PSMA PET CT versus planar bone scan and CT in prostate cancer patients progressing while on androgen deprivation therapy.
    Nikitas J, Gafita A, Benz MR, Djaïleb L, Farolfi A, Hotta M, Sonni I, Alano R, Rettig M, Shen J, Armstrong W, Grogan T, Liu S, Czernin J, Calais J.
    Sci Rep; 2024 Oct 18; 14(1):24411. PubMed ID: 39420060
    [Abstract] [Full Text] [Related]

  • 7. Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer.
    Aggarwal R, Wei X, Kim W, Small EJ, Ryan CJ, Carroll P, Cooperberg M, Evans MJ, Hope T.
    Eur Urol Oncol; 2018 May 18; 1(1):78-82. PubMed ID: 31100231
    [Abstract] [Full Text] [Related]

  • 8. Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer.
    Afshar-Oromieh A, Debus N, Uhrig M, Hope TA, Evans MJ, Holland-Letz T, Giesel FL, Kopka K, Hadaschik B, Kratochwil C, Haberkorn U.
    Eur J Nucl Med Mol Imaging; 2018 Nov 18; 45(12):2045-2054. PubMed ID: 29980832
    [Abstract] [Full Text] [Related]

  • 9. Enhancing PSMA-uptake with androgen deprivation therapy - a new way to detect prostate cancer metastases?
    Leitsmann C, Thelen P, Schmid M, Meller J, Sahlmann CO, Meller B, Trojan L, Strauss A.
    Int Braz J Urol; 2019 Nov 18; 45(3):459-467. PubMed ID: 30901173
    [Abstract] [Full Text] [Related]

  • 10. Bone Flare to Androgen Deprivation Therapy in Metastatic, Hormone-Sensitive Prostate Cancer on 68Ga-Prostate-Specific Membrane Antigen PET/CT.
    Zacho HD, Petersen LJ.
    Clin Nucl Med; 2018 Nov 18; 43(11):e404-e406. PubMed ID: 30222680
    [Abstract] [Full Text] [Related]

  • 11. Initial [18F]DCFPyL PET/CT in treatment-naïve prostate cancer: correlation with post-ADT PSA outcomes and recurrence.
    Li Y, Wang S, Zhao S, Zhao P, Huang S, Li K, Han S, Tian C, Li X, Shi B, Li X.
    Eur J Nucl Med Mol Imaging; 2024 Jul 18; 51(8):2458-2466. PubMed ID: 38563882
    [Abstract] [Full Text] [Related]

  • 12. Changes in Management After 18F-DCFPyL PSMA PET in Patients Undergoing Postprostatectomy Radiotherapy, with Early Biochemical Response Outcomes.
    Ng M, Guerrieri M, Wong LM, Taubman K, Sutherland T, Benson A, Byrne G, Koschel S, Yap K, Starmans M, Ong G, Macleod C, Foo M, Chao M.
    J Nucl Med; 2022 Sep 18; 63(9):1343-1348. PubMed ID: 35058320
    [Abstract] [Full Text] [Related]

  • 13. Outcome after PSMA-PET/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy.
    Rogowski P, Trapp C, von Bestenbostel R, Eze C, Ganswindt U, Li M, Unterrainer M, Zacherl MJ, Ilhan H, Beyer L, Kretschmer A, Bartenstein P, Stief C, Belka C, Schmidt-Hegemann NS.
    Eur J Nucl Med Mol Imaging; 2022 Mar 18; 49(4):1417-1428. PubMed ID: 34628521
    [Abstract] [Full Text] [Related]

  • 14. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics.
    Beheshti M, Haim S, Zakavi R, Steinmair M, Waldenberger P, Kunit T, Nader M, Langsteger W, Loidl W.
    J Nucl Med; 2013 Jun 18; 54(6):833-40. PubMed ID: 23559588
    [Abstract] [Full Text] [Related]

  • 15. Bone and Lymph Node Flare to Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer on 18F-Prostate-Specific Membrane Antigen PET/CT With Decreasing Prostate-Specific Antigen of 0.7 ng/mL.
    Lu Y.
    Clin Nucl Med; 2022 Jul 01; 47(7):664-665. PubMed ID: 35175941
    [Abstract] [Full Text] [Related]

  • 16. The roles of 68 Ga-PSMA PET/CT and 18 F-FDG PET/CT imaging in patients with triple-negative breast cancer and the association of tissue PSMA and claudin 1, 4, and 7 levels with PET findings.
    Arslan E, Ergül N, Beyhan E, Erol Fenercioglu Ö, Sahin R, Cin M, Battal Havare S, Can Trabulus FD, Mermut Ö, Akbas S, Fikret Çermik T.
    Nucl Med Commun; 2023 Apr 01; 44(4):284-290. PubMed ID: 36756767
    [Abstract] [Full Text] [Related]

  • 17. A Prospective Trial of 68Ga-PSMA and 18F-FDG PET/CT in Nonmetastatic Prostate Cancer Patients with an Early PSA Progression During Castration.
    Wang B, Liu C, Wei Y, Meng J, Zhang Y, Gan H, Xu X, Wan F, Pan J, Ma X, Hu S, Freedland SJ, Song S, Ye D, Zhu Y.
    Clin Cancer Res; 2020 Sep 01; 26(17):4551-4558. PubMed ID: 32527944
    [Abstract] [Full Text] [Related]

  • 18. 68Ga-PSMA-11 PET/CT Follow-Up of Patients with Prostate Cancer with Bone Metastases Who Had Reduced Bone Density after Androgen Deprivation Therapy.
    Kesler M, Druckmann I, Levine C, Kuten J, Yossepowitch O, Even-Sapir E.
    Diagnostics (Basel); 2021 Feb 10; 11(2):. PubMed ID: 33578990
    [Abstract] [Full Text] [Related]

  • 19. Impact of 18F-fluciclovine PET/CT on plans for androgen deprivation therapy in patients with biochemical recurrence of prostate cancer: data analysis from two prospective clinical trials.
    Andriole GL, Scarsbrook AF, Savir-Baruch B, LOCATE/FALCON Study Groups.
    Urol Oncol; 2023 Jun 10; 41(6):293.e1-293.e7. PubMed ID: 37121865
    [Abstract] [Full Text] [Related]

  • 20. [18F]-JK-PSMA-7 and [18F]-FDG tumour PET uptake in treated xenograft human prostate cancer model in mice.
    Van Simaeys G, Doumont G, De Maeseneire C, Passon N, Lacroix S, Lentz C, Horion A, Warnier C, Torres D, Martens C, Vierasu I, Egrise D, Goldman S.
    Eur J Nucl Med Mol Imaging; 2021 Jun 10; 48(6):1773-1784. PubMed ID: 33398412
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.